BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 19, 2026
Home » Blogs » BioWorld MedTech Perspectives » Promising NEC research on the horizon

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Diagnostics

Promising NEC research on the horizon

May 3, 2013
By Omar Ford

If someone would have asked me three years ago what Necrotizing enterocolitis (or NEC for short) meant, then my response would probably be a blank stare, followed by I'll have to get back to you on that. That's often the reply I give to people when I'm not sure of an answer.

But if someone were to ask me today what NEC means, the answer would probably be a bit different. I think the first thing I'd say is, "Well how much time do you have for me to answer that question honestly?" For simplicity's sake, we can just say that it is a condition often seen in premature infants where portions of the bowel undergo necrosis or tissue death. It impacts about 10% of infants born at under 29 weeks, and about a third will die.

My family found out first hand what this disease is when it claimed the life of my 3-week-old son, Aaron. Now, there's not a day that goes by when I don't think about my son or the disease and how it changed the life of my family.

Last month, however, I stumbled across some interesting research that might give other parents who have premature infants a chance to diagnose and catch the disease before it can do much harm. Researchers have discovered that abnormal gut bacteria in premature babies can be found days before the onset of NEC according to a study in BioMed Central's open access journal Microbiome. The research also shows that babies who later went on to develop NEC had a lower diversity of gut bacteria 4-9 days after birth, increased level of Firmicutes or Enterobacteriaceae, and lacked the Propionibacterium found in healthy babies. In other words, this could eventually turn out to be a strong predictor of NEC. But it's still in the initial phases.

I put this in MDD's special section Diagnostics Extra, nearly two weeks ago. I'm going to be honest with you, it was perhaps one of the hardest things that I've ever done. At some point I selfishly asked myself why couldn't they have had something like this for Aaron - why couldn't this research be fully realized and used. But, then I realized that the news needs to get out and that there needs to be some strong awareness regarding the disease.

I thought it only fitting that perhaps - I write about this now, to not only get the awareness out about this research, but also to give my son a voice, who - if he survived - would turn 3-years-old on Monday.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing